Delivery Order SPE2DB22D1017-SPE2DB25FYPYB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $5,569.72. This competitive delivery order, structured as a firm fixed-price contract with no set-aside designation, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,212.12 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 24,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This contract, which is non-competitive and carries a firm fixed-price structure, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The order is scheduled for completion by August 14, 2025, and will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a $1,725.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon DR 100s, with a ceiling value of $18,568.25. The contract, executed on September 3, 2025, with an ultimate completion date of September 4, 2025, utilizes firm fixed-price pricing under a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on September 4, 2025, with a ceiling value of $1,616.16 and completion date of September 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under a larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This firm fixed-price delivery order, valued at $11,775.31, represents a competitively awarded contract with an ultimate completion date of August 29, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $46,171.42. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $45,421.87 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s. This contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was competitively procured and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Creon is a pancreatic enzyme replacement...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPYBDelivery Order
The Defense Logistics Agency awarded a $5,151.86 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Creon DR 12,000 unit capsules in packages of 100 units. This is a firm fixed price delivery order with no set-aside designation, reflecting an open competitive award to this major pharmaceutical distributor. The order is scheduled for completion by September 5, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, supplying specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. The current order for Creon DR, a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency in military personnel and beneficiaries, exemplifies the routine fulfillment of critical pharmaceutical needs through this strategic vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 9/4/25 |